Nf-kB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Nakshatri, H ^a   Appaiah, H N ^a   Anjanappa, M ^a   Gilley, D ^a   Tanaka, H ^a   Badve, S ^a   Crooks, P A ^b   Mathews, W ^c   Sweeney, C ^d   Bhat Nakshatri, P ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c Leuchemix Inc   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIMETHYLAMINOPARTHENOLIDE; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE 1; HISTONE H3; PARTHENOLIDE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC-1 COMPOUND; LYSINE; MEMBRANE PROTEIN; NF-KAPPAB INHIBITOR ALPHA; NSD1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SESQUITERPENE; SET2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR RELA; TUMOR MARKER;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELLS BY BODY ANATOMY; DNA METHYLATION; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; GENE REPRESSION; GENOMIC INSTABILITY; HISTONE MODIFICATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SUBUNIT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLADDER TUMOR; BREAST TUMOR; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; HUMAN GENOME; METABOLISM; METHYLATION; PATHOLOGY; PROGNOSIS; PROTEIN PROCESSING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; I-KAPPA B PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSINE; MEMBRANE PROTEINS; METHYLATION; MICE; NF-KAPPA B; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; SESQUITERPENES; TRANSCRIPTION FACTOR RELA; URINARY BLADDER NEOPLASMS;

EID: 84927628424     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.569     Document Type: Article

References (55)

1. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
3. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
4. Kanno R, Janakiraman H, Kanno M. Epigenetic regulator polycomb group protein complexes control cell fate and cancer. Cancer Sci 2008; 99: 1077-1084.
5. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128: 735-745.
6. Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 2012; 13: 115-126.
7. Schmidt CK, Jackson SP. On your mark, get SET(D2), go! H3K36me3 primes DNA mismatch repair. Cell 2013; 153: 513-515.
8. Lucio-Eterovic AK, Singh MM, Gardner JE, Veerappan CS, Rice JC, Carpenter PB. Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proc Natl Acad Sci USA 2010; 107: 16952-16957.
9. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA 2009; 106: 21830-21835.
10. Weinstein JN, Lorenzi PL. Cancer: discrepancies in drug sensitivity. Nature 2013; 504: 381-383.
11. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 2012; 109: 2730-2735.
12. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804-812.
13. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011; 44: 609-620.
14. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
15. Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 2011; 286: 7983-7989.
16. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
17. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004; 18: 1251-1262.
18. Stender JD, Pascual G, Liu W, Kaikkonen MU, Do K, Spann NJ et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell 2012; 48: 28-38.
19. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
20. Benetti R, Gonzalo S, Jaco I, Schotta G, Klatt P, Jenuwein T et al. Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination.J Cell Biol 2007; 178: 925-936.
21. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
22. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007; 130: 1083-1094.
23. Gopal YN, Arora TS, Van Dyke MW. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasiamutated. Chem Biol 2007; 14: 813-823.
24. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P et al. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 2009; 329: 505-514.
25. Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S et al. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species. Int J Cancer 2011; 128: 2481-2494.
26. Price BD, D'Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell 2013; 152: 1344-1354.
27. Modak R, Das Mitra S, Krishnamoorthy P, Bhat A, Banerjee A, Gowsica BR et al. Histone H3K14 and H4K8 hyperacetylation is associated with Escherichia coli-induced mastitis in mice. Epigenetics 2012; 7: 492-501.
28. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000; 19: 4159-4169.
29. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. EMBO J 2003; 22: 5530-5539.
30. Nozaki S, Sledge GW Jr, Nakshatri H. Repression of GADD153/CHOP by NF-kappaB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 2001; 20: 2178-2185.
31. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155-1164.
32. Lin YC, Hsu EC, Ting LP. Repression of hepatitis B viral gene expression by transcription factor nuclear factor-kappaB. Cell Microbiol 2009; 11: 645-660.
33. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18.
34. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007; 26: 711-724.
35. Kapoor-Vazirani P, Kagey JD, Vertino PM. SUV420H2-mediated H4K20 trimethylation enforces RNA polymerase II promoter-proximal pausing by blocking hMOF-dependent H4K16 acetylation. Mol Cell Biol 2011; 31: 1594-1609.
36. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13: 297-311.
37. Lu T, Jackson MW, Singhi AD, Kandel ES, Yang M, Zhang Y et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci USA 2009; 106: 16339-16344.
38. Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10, an NF-kappaB-dependent antiapoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ 2011; 18: 1184-1195.
39. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004; 23: 7330-7344.
40. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
41. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
42. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040-4048.
43. Goswami CP, Nakshatri H. PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinformatics 2013; 3: 22.
44. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
45. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormoneindependent growth. Mol Cell Biol 1997; 17: 3629-3639.
46. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12: S37-S46.
47. Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005; 4: 33-41.
48. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2013; 15: 49-63.
49. Huang N, vom Baur E, Garnier JM, Lerouge T, Vonesch JL, Lutz Y et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 1998; 17: 3398-3412.
50. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
51. Xie P, Tian C, An L, Nie J, Lu K, Xing G et al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal 2008; 20: 1671-1678.
52. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S. Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev 2008; 22: 1159-1173.
53. Beauchef G, Bigot N, Kypriotou M, Renard E, Poree B, Widom R et al. The p65 subunit of NF-kappaB inhibits COL1A1 gene transcription in human dermal and scleroderma fibroblasts through its recruitment on promoter by protein interaction with transcriptional activators (c-Krox, Sp1, and Sp3). J Biol Chem 2012; 287: 3462-3478.
54. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments]. Science 1996; 274: 782-784.
55. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF et al. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.